Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 15 to 23 amino acid residues in defined sequence
Reexamination Certificate
2006-04-18
2006-04-18
Harris, Alana M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
15 to 23 amino acid residues in defined sequence
C530S300000, C514S001000, C514S002600, C514S004300, C514S008100, C514S013800, C424S184100, C424S185100, C436S064000, C436S086000
Reexamination Certificate
active
07030211
ABSTRACT:
This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.
REFERENCES:
patent: 5968506 (1999-10-01), Weinrich et al.
patent: 6166178 (2000-12-01), Cech et al.
patent: 92/14756 (1992-09-01), None
patent: 97/35619 (1997-10-01), None
patent: 98/01542 (1998-01-01), None
patent: 98/14593 (1998-04-01), None
patent: 99/50386 (1999-10-01), None
patent: 99/50392 (1999-10-01), None
Nijman et al. p53, a potential target for tumor-directed T cells. Immunology Letters 40: 171-178, 1994.
GenCore database sequence alignment between Applicants' SEQ ID NO: 2 and U.S. Patent No. 6,166,178 sequence 31.
Vonderheide, R.H., et al., “The Telomerase Catalytic Subunit Is a Widely Expressesd Tumor-Associated Antigen Recognized by Cytotoxic T Lymphocytes,” Immunity, vol. 10, pp. 673-679. 1999.
Meyerson, M., et al., “hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and During Immortalization,” Cell, vol. 90, pp. 785-795, 1997.
Nakamura, T.M., et al., “Telomerase Catalytic Subunit Homologs from Fission Yeast and Human,” Science, vol. 277, pp. 955-959, 1997.
Harrington, L., et al., “A Mammalian Telomerase-Associated Protein,” Science, vol. 275, pp. 973-977, 1997.
Nakayama, J., et al., “TLP1: A Gene Encoding a Protein Component of Mammalian Telomerasse Is a Novel Member of WD Repeats Family,” Cell, vol. 88, pp. 875-884, 1997.
Gaudernack, G., “T cell responses against mutant ras: a basis for novel cancer vaccines,” Immunotechnology, vol. 2, pp. 3-9, 1996.
Gjertsen, M.K., et al., “Ex Vivo ras Peptide Vaccination In Patients With Advanced Pancreatic Cancer: Results of a Phase I/II Study,” Int. J. Cancer, vol. 65, pp. 450-453, 1996.
Gjertsen, M. K., et al., “Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination,” British J. of Cancer, vol. 74, pp. 1828-1833, 1996.
Gjertsen, M. K., et al., “Cytotoxic CD4+and CD8+Lymphocytes, Generated by Mutant p21-ras(12 VAL) Peptide Vaccination of a Patient, . . . This Mutation,” Int. J. Cancer, vol. 72, pp. 784-790, 1997.
Gjertsen, M.K., et al., “Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer,” Vox Sanguinis, vol. 74 (Suppl. 2), pp. 489-495, 1998.
Rammensee, H-G., et al., “MHC ligands and peptide motifs: first listing,” Immunogenetics, vol. 41, No. 4, pp. 178-228, 1995.
Barinaga, M., “Getting Some “Backbone”: How MHC Binds Peptides,” Science, vol. 257, pp. 880-881, 1992.
Greider, C.W., et al., “Identification of a Specific Telomere Terminal Transferase Activity in Tetrahymena Extracts,” Cell, vol. 43, pp. 405-413, 1985.
Collins, K., et al., “Purification of Tetrahymena Telomerase and Cloning of Genes Encoding the Two Protein Components of the Enzyme,” Cell, vol. 81, pp. 677-686, 1995.
Harley, C.B., et al., “Telomerase, Cell Immortality, and Cancer,” Cold Spring Harbor Symp. Quant. Biol., vol. 59, pp. 307-315, 1994.
Kim, N.W., et al., “Specific Association of Human Telomerase Activity with Immortal Cells and Cancer,” Science, vol. 266, pp. 2011-2015, 1994.
Broccoli, D., et al., “Telomerase activity in normal and malignant hematopoietic cells,” Proc. Natl. Acad. Sci. USA, vol. 92, No. 20, pp. 9082-9086, 1995.
Counter, C.M., et al., “Telomerase Activity in Normal Leukocytes and in Hematologic Malignancies,” Blood, vol. 85, No. 9, pp. 2315-2320, 1995.
Hiyama, K., et al., “Activation of Telomerase in Human Lymphocytes and Hematopoietic Progenitor Cells,” J. Immunology, vol. 155, No. 8, pp. 3711-3715, 1995.
Counter, C.M., et al., “Telomerase activity in human ovarian carcinoma,” Proc. Natl. Acad. Sci. NAS USA, vol. 91, No. 8, pp. 2900-2904, 1994.
Shay, J.W., et al., “A Survey of Telomerase Activity in Human Cancer,” Eur. J. Cancer, vol. 33, No. 5, pp. 787-791, 1997.
Klingelhutz, A.J., et al., “Telomerase activation by the E6 gene product of human papillomavirus type 16,” Nature, vol. 380, No. 6569, pp. 79-82, 1996.
Sharma, S., et al., “Preclinical and clinical strategies for development of telomerase and telomere inhibitors,” Annals of Oncology, vol. 8, No. 11, pp. 1063-1074, 1997.
Axelrod, N., “Of telomeres and tumors,” Nature Medicine, vol. 2, No. 2, pp. 158-159, 1996.
Huminiecki, L., “Telomerase as a therapeutic target,” Acta Biochimica Polonica, vol. 43, No. 3, pp. 531-538, 1996.
Soria, J-C., et al., “Télomères, télomérase et cancer,” Bull. Cancer, vol. 84, No. 10, pp. 963-970, 1997. (Abstract in English).
Dahse, R., et al., “Telomeres and telomerase: biological and clinical importance,” Clinical Chemistry, vol. 43, No. 5, pp. 708-714, 1997.
Deres, K., et al., “In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine,” Nature, vol. 342, No. 6249, pp. 561-564, 1989.
Tighe, H., et al., “Gene vaccination: plasmid DNA is more than just a blueprint,” Immunology Today, vol. 19, No. 2, pp. 89-97, 1998.
Lurquin, C., et al., “Structure of the Gene of Tum Transplantation Antigen P91A: The Mutated Exon Encodes a Peptide Recognized with Ldby Cytolytic T Cells”, Cell, vol. 58, pp. 293-303, 1989.
Robert H. Vonderheide, et al., “The Telomerase Catalytic Subunit Is a Widely Expressed Tumor-Associated Antigen Recognized by Cytotoxic T Lymphocytes,” Immunity, vol. 10, Jun. 1999, pp. 673-679.
Kenneth C. Parker, et al., “Sequence Motifs Important for Peptide Binding to the Human MHC Class I Molecule, HLA-A2,” J. Immunol., Vol. 149, No. 11, Dec. 1992, pp. 3580-3587.
Kenneth C. Parker, et al., “Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptides Side-Chains,” J. Immunol., vol. 152, No. 1, Jan. 1994, pp. 163-175.
Toru M. Nakamura, et al., “Telomerase Catalytic Subunit Homologs from Fission Yeast and Human,” Science, vol. 277, Aug. 15, 1997, pp. 955-959.
Miles P. Davenport, et al., “An Empirical Method for the Predication of T-Cell Epitopes,” Immunogenetics, vol. 42, No. 5, 1995, pp. 392-397.
Gabriel E. Meister, et al., “Two Novel T Cell Epitope Prediction Algorithms Based on MHC-Binding Motifs; Comparison of Predicted and Published Epitopes fromMycobacterium tuberculosisand HIV Protein Sequences,” Vaccine, vol. 13, No. 6, 1995, pp. 581-591.
Juergen Hammer, et al., “HLA Class II Peptide Binding Specificity and Autoimmunity,” Advances in Immunology, vol. 66, 1997, pp. 67-100.
HLA Peptide Search Results Ranking Potential 9-mer Peptides Based on a Predicted Half-time Dissociation to HLA Class I Molecule A—1101 Using the Algorithm available at http://bimas.dcrt.nih.gov/cgi-bin/molbio/ken—parker—combofrom, printed May 7, 2004.
HLA Peptide Search Results Ranking Potential 9-mer Peptides Based on a Predicted Half-time Dissociation to HLA Class I Molecule A3 Using the Algorithm available at http://bimas.dcrt.nih.gov/cgi-bin/molbio/ken—parker—combofrom, printed May 7, 2004.
HLA Peptide Search Results Ranking Potential 9-mer Peptides Based on a Predicted Half-time Dissociation to HLA Class I Molecule A—0201 Using the Algorithm available at http://bimas.dcrt.nih.gov/cgi-bin/molbio/ken
Eriksen Jon Amund
Gaudernack Gustay
Gjertsen Marianne Klemp
Møller Mona
Sæbøe-Larsen Stein
Fitzpatrick ,Cella, Harper & Scinto
GemVax AS
Harris Alana M.
LandOfFree
Antigenic peptides derived from telomerase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antigenic peptides derived from telomerase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigenic peptides derived from telomerase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3610158